急性探索性苯丙胺盐药物在未接触苯丙胺的儿童中的毒性:回顾性队列研究
该研究为单毒物中心2005年1月1日至2018年11月30日的回顾性队列,纳入0-12岁未接触苯丙胺儿童单物质摄入治疗注意缺陷多动障碍(ADHD)的苯丙胺盐且随访至已知结局的160例(筛查1394例)。有症状患者的中位剂量(1.38 mg/kg)高于无症状者(0.83 mg/kg);接受苯二氮卓类药物的患者中位剂量(1.58 mg/kg)也高于未接受者(1.0 mg/kg)。>0.75 mg/kg阈值对接受苯二氮卓类药物的敏感性为100%、特异性为36.8%,对出现任何症状的敏感性为93.9%、特异性为47.4%。作者结论认为接受苯二氮卓类药物的患者摄入中位剂量高于未接受者,且≤0.75 mg/kg无一例接受苯二氮卓类药物,并建议开展前瞻性研究评估分诊指南和转诊剂量。
要点
- 160例0-12岁未接触苯丙胺儿童单物质摄入ADHD用苯丙胺盐,有症状者中位剂量1.38 mg/kg高于无症状者0.83 mg/kg。
- 接受苯二氮卓类药物的患者中位摄入剂量1.58 mg/kg,高于未接受者的1.0 mg/kg。
- 摄入剂量>0.75 mg/kg对接受苯二氮卓类药物的敏感性为100%、特异性为36.8%。
- 摄入剂量>0.75 mg/kg对出现任何症状的敏感性为93.9%、特异性为47.4%。
- 摄入剂量≤0.75 mg/kg的儿童无一例接受苯二氮卓类药物。
适用人群与场景
- 0-12岁未接触苯丙胺的儿童,单物质摄入用于治疗ADHD的苯丙胺盐,随访至已知结局。
诊断标准与关键阈值
- 剂量阈值>0.75 mg/kg对接受苯二氮卓类药物的敏感性为100%、特异性为36.8%,对出现任何症状的敏感性为93.9%、特异性为47.4%。
研究设计与关键结果
- 单毒物中心回顾性研究,2005年1月1日至2018年11月30日,筛查1394例,160例符合纳入标准;平均年龄1.8岁,55%为男性。
- 有症状患者中位剂量1.38 mg/kg,高于无症状患者的0.83 mg/kg。
- 接受苯二氮卓类药物的患者中位剂量1.58 mg/kg,高于未接受者的1.0 mg/kg。
- 剂量阈值>0.75 mg/kg对接受苯二氮卓类药物的敏感性100%、特异性36.8%,对出现任何症状的敏感性93.9%、特异性47.4%。
- 摄入剂量≤0.75 mg/kg的儿童无一例接受苯二氮卓类药物。
证据类型、等级与局限
- 证据类型:单毒物中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,摄入剂量≤0.75 mg/kg的未接触苯丙胺儿童无一例接受苯二氮卓类药物。
- 作者建议开展前瞻性研究评估分诊指南和转诊剂量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background and Objectives: Pediatric ingestions of amphetamines used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) are on the rise. Little data provide an amphetamine dose at which to refer pediatric unintentional ingestions to a healthcare facility for monitoring. We studied the dose at which unintentional ingestions of amphetamines develop symptoms and receive benzodiazepines.Methods: We performed a retrospective study from a single poison center from 1/1/2005 through 11/30/2018. We included single substance ingestion of amphetamine salts to treat ADHD in amphetamine-naïve children age 0-12 years followed to a known outcome. Poison center documentation was reviewed for signs and symptoms related to amphetamine toxicity and use of benzodiazepines.Results: We screened 1,394 cases and 160 met inclusion criteria. The mean age of patients was 1.8 years and 55% were male. The median dose of symptomatic patients (1.38 mg/kg) was greater than those without symptoms (0.83 mg/kg). The median amphetamine dose of patients receiving benzodiazepines (1.58 mg/kg) was also greater than for patients not receiving benzodiazepines (1.0 mg/kg). A dose threshold of greater than 0.75 mg/kg was 100% sensitive and 36.8% specific for benzodiazepine administration and 93.9% sensitive and 47.4% specific for presence of any symptoms.Conclusions: The median dose of amphetamines ingested by patients receiving benzodiazepines was greater than those not receiving benzodiazepines. No child with a dose of ≤0.75 mg/kg received benzodiazepines. Prospective studies should be performed to assess triage guidelines and referral doses.
参考来源
- Leonard JB, Howard AK, Hines EQ, et al. Toxicity of acute exploratory amphetamine-salt medication in amphetamine-naïve pediatrics: a retrospective cohort study. Clin Toxicol (Phila). 2020. PMID: 31913713. doi:10.1080/15563650.2019.1703997
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。